DK0699075T3 - Modificeret faktor VII - Google Patents

Modificeret faktor VII

Info

Publication number
DK0699075T3
DK0699075T3 DK94918092T DK94918092T DK0699075T3 DK 0699075 T3 DK0699075 T3 DK 0699075T3 DK 94918092 T DK94918092 T DK 94918092T DK 94918092 T DK94918092 T DK 94918092T DK 0699075 T3 DK0699075 T3 DK 0699075T3
Authority
DK
Denmark
Prior art keywords
factor vii
modified
modified factor
treat
factor
Prior art date
Application number
DK94918092T
Other languages
Danish (da)
English (en)
Inventor
Lars Christian Petersen
Kathleen L Berkner
Charles E Hart
Original Assignee
Novo Nordisk As
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Novo Nordisk Healthcare Ag filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK0699075T3 publication Critical patent/DK0699075T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94918092T 1993-05-21 1994-05-23 Modificeret faktor VII DK0699075T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6572593A 1993-05-21 1993-05-21
PCT/US1994/005779 WO1994027631A1 (en) 1993-05-21 1994-05-23 Modified factor vii

Publications (1)

Publication Number Publication Date
DK0699075T3 true DK0699075T3 (da) 2002-03-11

Family

ID=22064676

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94918092T DK0699075T3 (da) 1993-05-21 1994-05-23 Modificeret faktor VII

Country Status (11)

Country Link
EP (1) EP0699075B1 (pt)
JP (1) JPH08510746A (pt)
AT (1) ATE210458T1 (pt)
AU (1) AU703110B2 (pt)
CA (1) CA2162726A1 (pt)
DE (1) DE69429429T2 (pt)
DK (1) DK0699075T3 (pt)
ES (1) ES2169074T3 (pt)
HU (1) HU219682B (pt)
PT (1) PT699075E (pt)
WO (1) WO1994027631A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
IL154520A0 (en) * 2000-09-13 2003-09-17 Novo Nordisk As Human coagulation factor vii variants
BR0113854A (pt) 2000-09-13 2004-07-06 Novo Nordisk As Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
PL371800A1 (en) 2001-03-22 2005-06-27 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
AU2002336920A1 (en) * 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
SI1499719T1 (sl) 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
EP1517698B2 (en) 2002-06-21 2017-12-06 Novo Nordisk Health Care AG STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US20060166874A1 (en) * 2002-09-30 2006-07-27 Haaning Jesper M Fvii or fviia variants having increased clotting activity
WO2004041302A1 (en) * 2002-11-06 2004-05-21 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator
WO2004083361A2 (en) 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
WO2004103398A1 (en) 2003-05-23 2004-12-02 Novo Nordisk Health Care Ag Protein stabilization in solution
CA2529828C (en) 2003-06-19 2013-01-15 Maxygen Holdings Ltd. Factor vii or viia gla domain variants
JP4658041B2 (ja) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20090042784A1 (en) * 2004-09-29 2009-02-12 Janus Krarup Purification of a Drug Substance of a Factor VII Polypeptide by Removal of DesGla-Factor VII Polypeptide Structures
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
ES2856968T3 (es) 2016-01-15 2021-09-28 Rigshospitalet Adquisición de imágenes de TEP cuantitativas de la expresión de factor tisular usando factor VII inhibido en el punto activo y marcado con 18F
MA46864A (fr) 2016-11-17 2021-04-28 Minerva Imaging Aps Facteur vii inhibé par le site actif marqué par 177-lu

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521873B1 (en) * 1990-01-29 1999-06-02 Zymogenetics, Inc. Anticoagulant proteins
JP3459416B2 (ja) * 1991-02-28 2003-10-20 ザイモジェネティクス，インコーポレイティド 修飾されたファクター▲ｖｉｉ▼

Also Published As

Publication number Publication date
WO1994027631A1 (en) 1994-12-08
EP0699075A1 (en) 1996-03-06
ES2169074T3 (es) 2002-07-01
AU703110B2 (en) 1999-03-18
HU219682B (hu) 2001-06-28
DE69429429T2 (de) 2002-05-16
AU6956094A (en) 1994-12-20
HUT73329A (en) 1996-07-29
HU9503312D0 (en) 1996-01-29
ATE210458T1 (de) 2001-12-15
CA2162726A1 (en) 1994-12-08
DE69429429D1 (de) 2002-01-24
JPH08510746A (ja) 1996-11-12
EP0699075B1 (en) 2001-12-12
PT699075E (pt) 2002-05-31

Similar Documents

Publication Publication Date Title
DK0699075T3 (da) Modificeret faktor VII
MX9702951A (es) Factor vii modificado.
DE69233398D1 (de) Modifizierter faktor-vii
HUP0003077A2 (hu) Módosított VII faktor
DE69331643D1 (de) Zwischenprodukte zur Herstellung retroviraler proteasehemmenden Verbindungen
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
PT96103A (pt) Processo para a preparacao de proteinas fibrinoliticas e anti-tromboticas activaveis
ATE177752T1 (de) Neue inhibitoren von faktor xa
MY119155A (en) New peptide derivatives
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
DE69006851D1 (de) Blutgerinnungshemmende zusammensetzungen aus faktor xa.
ATE203905T1 (de) Thrombin inhibitor
ATE275950T1 (de) Intravenösen verabreichung von valproat zur behandlung von migränekopfschmerzen
RU95113437A (ru) (h±)-сложный этиловый эфир транс-2-диметиламино-1-фенил-3-циклогексентранс-1-карбоновой кислоты в виде первичного ортофосфата и твердая фармацевтическая композиция с обезболивающей активностью
RU95109909A (ru) Способ ингибирования ретровирусной инфекции, ингибитор протеазы, кодирующая его нуклеиновая кислота и способ рекомбинантного продуцирования серинового ингибитора
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
ATE245983T1 (de) Inhibitoren der nuklearen lokalisierung von hiv
FI883730A (fi) Etrar och tioetrar med terapeutisk effekt, framstaellning av dessa och farmaceutiska sammansaettningar som innehaoller dem.